Jenburkt Pharmaceuticals share price
NSE: JENBURPHBSE: 524731Pharmaceuticals & BiotechnologySmall Cap
Last close ₹870.95down ₹0.45 (0.05%)BSE ₹860.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹871.40.
52-week range of BSE trades to 23 Oct 2026
₹852.00Low, 23 Oct 2026₹1,321.00High, 31 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹384 Cr1,871st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 6 Aug 2026
- 11.7
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹3.95 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 10.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 5 May 2026
- 2.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.38%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 6 Aug 2026
- 17.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹3.95 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 6 Aug 2026
- 19.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 5 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 2,34093.5% delivered
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 6 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹36 Crdown 20.43%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹5.89 Crdown 45.75%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 16.6%
Revenue by year
Peak revenue ₹169 Cr, year to Mar 2026
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 5 Nov | Dec 2024Filed 28 Jan | Mar 2025Filed 13 Aug | Jun 2025Filed 12 Aug | Sep 2025Filed 30 Dec | Dec 2025Filed 3 Feb | Mar 2026Filed 5 May | Jun 2026Filed 6 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 41.2 | 36.9 | 41.0 | 35.5 | 45.6 | 43.0 | 44.6 | 35.5 |
| Net profit | 9.6 | 6.5 | 8.5 | 7.8 | 10.2 | 5.9 | 10.8 | 5.9 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 23.3% | 17.6% | 20.8% | 21.9% | 22.3% | 13.8% | 24.3% | 16.6% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 5% of 2,324 trading days since Jun 2017.
LowestHighest
Its median13.2Industry median28.3
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 2% of 1,975 trading days since Nov 2018.
LowestHighest
Its median2.5Industry median2.9
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.8.1
At or below today's level on 45% of 1,975 trading days since Nov 2018.
LowestHighest
Its median8.4Industry median18.7
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 93% of 2,441 trading days over the last 10 years.
LowestHighest
Its median1.71%Industry median0.51%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −3.4% | +8.3% | −12.8% | 2.2% |
| 3 years | +14.8% | +12.2% | +0.5% | 2.1% |
| 5 years | +21.2% | +17.0% | +1.8% | 2.1% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 1, 3 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2026.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Jenburkt Pharmaceuticals in market cap. 1 company in the table last traded before then: its row is priced on its last trade.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Trident LifelineTLL | 488 | 23.2 | 4.9 | – | – | – | 25.5% | – | 0.00% |
 Haleos LabsHALEOSLABS | 453 | 28.7 | 2.1 | 13.7 | −3.1% | −8.5% | 7.7% | 7.4% | 0.10% |
 Infinium PharmachemINFINIUM | 446 | 36.7 | 3.7 | – | +21.8% | +41.8% | 10.5% | – | 0.00% |
 Albert DavidALBERTDAVD | 436 | 19.3 | 1.1 | 16.1 | +11.4% | +258.5% | 5.8% | 4.1% | 0.65% |
 Medicamen BiotechMEDICAMEQ | 344 | – | 1.2 | 18.5 | +24.7% | – | – | 3.7% | 0.39% |
 Aarey Drugs & PharmaceuticalsAAREYDRUGS | 340 | – | – | – | −7.7% | – | – | 1.8% | 0.00% |
 Astonea LabsASTONEALAB | 340 | 75.2 | 5.9 | – | – | – | 12.0% | – | 0.00% |
 Lyka LabsLYKALABS | 293 | – | 3.2 | – | −2.6% | – | −9.2% | −8.0% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹20.70 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 28 Aug 2026 | Final | ₹20.70 |
| 11 Jul 2025 | Final | ₹18.00 |
| 23 Jul 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹15.30 |
| 19 Jul 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹14.40 |
| 21 Jul 2022 | Final | ₹12.00 |
| 30 Aug 2021 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹10.20 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
22 Sep · Intimation Regarding Admission Of Equity Shares Of The Company Under 'Permitted To Trade' Category On National Stock Exchange Of India Limited.
Jenburkt Pharmaceuticals share price by year
Each calendar year to 2025.Jenburkt Pharmaceuticals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025BSE close | 1,089.80 | −10.3% | 1,392.65 | 938.05 |
| 2024BSE close | 1,214.70 | +78.6% | 1,326.70 | 678.45 |
| 2023BSE close | 680.15 | +4.6% | 773.50 | 610.10 |
| 2022BSE close | 650.00 | +22.0% | 680.35 | 467.10 |
| 2021BSE close | 533.00 | +24.5% | 572.50 | 392.50 |
| 2020BSE close | 428.00 | +5.7% | 485.00 | 275.25 |
| 2019BSE close | 405.05 | −30.9% | 585.30 | 391.50 |
| 2018BSE close | 585.85 | −5.8% | 857.05 | 522.00 |
| 2017BSE close | 622.10 | +25.6% | 627.70 | 401.35 |
| 2016BSE close | 495.40 | +7.8% | 564.15 | 342.65 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 860.00 | 879.80 | 850.00 | 870.95 | 855.13 | 2,340 | 93.5% |
| 22 Oct 2026 | 898.95 | 899.50 | 865.50 | 871.40 | 876.43 | 821 | 79.7% |
| 21 Oct 2026 | 903.05 | 917.80 | 881.00 | 891.75 | 899.11 | 1,241 | 83.2% |
| 19 Oct 2026 | 920.20 | 942.00 | 904.50 | 920.95 | 916.93 | 726 | 75.5% |
| 16 Oct 2026 | 911.25 | 935.00 | 911.25 | 923.45 | 921.54 | 708 | 61.7% |
| 15 Oct 2026 | 927.55 | 928.25 | 912.00 | 916.15 | 917.63 | 384 | 80.0% |
| 14 Oct 2026 | 930.40 | 930.40 | 915.00 | 920.00 | 923.80 | 359 | 76.9% |
| 13 Oct 2026 | 935.95 | 935.95 | 918.20 | 919.15 | 919.59 | 502 | 91.2% |
| 12 Oct 2026 | 926.00 | 940.00 | 885.00 | 924.45 | 924.86 | 2,978 | 79.7% |
| 9 Oct 2026 | 963.00 | 963.00 | 944.25 | 947.10 | 949.48 | 924 | 68.1% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Jenburkt Pharmaceuticals Limited
- NSE symbol
- JENBURPH
- BSE code
- 524731
- ISIN
- INE354A01013
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jan 1995
- Face value
- ₹10
- CIN
- L24230MH1985PLC036541
- Corporate identity number, the registrar of companies' code for it